Remove Immunization Remove Insurance Remove Packaging
article thumbnail

The MEK effect on cancer — a slow and steady approach to drug resistance

PharmaVoice

You just want to slash it, rip it out or attack it like an enemy target,” said Benjamin Zeskind, co-founder, CEO and president of Immuneering Corporation. To overcome that hurdle, Immuneering is testing an approach that slows cancer down rather than rushing to destroy it. You can unsubscribe at anytime.

article thumbnail

Is biopharma dealmaking getting hot again?

PharmaVoice

billion buyout of Blueprint Medicines doubled down on the French pharma giant’s focus on drugs that impact the immune system. Editors pick stock via Getty Images GLP-1 roadblocks: Discontinuation rates soar as insurers clamp down As more drugmakers aim for the lucrative weight loss market, patient challenges linger.

Insurance 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bharat Biotech acquires licence for GSK’s Shigella vaccine development

Pharmaceutical Technology

The technology utilises outer membrane vesicles (OMVs) to deliver antigens, often eliminating the need for adjuvants while triggering the immune response. Discovered and developed by GSK’s global health team scientists, the GMMA technology is a low-cost platform ideal for creating vaccines in resource-limited settings.

article thumbnail

EC approves argenx’s efgartigimod alfa for CIDP treatment

Pharmaceutical Technology

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP), an immune-mediated neuromuscular disorder of the peripheral nervous system.

article thumbnail

Juvenescence enhances AI drug discovery with Ro5 acquisition

Pharmaceutical Technology

This integration will reinforce Juvenescence’s pipeline in cardio-metabolism, cognition, immunity and cellular repair sectors. Incorporating Ro5’s AI platform into Juvenescence is expected to accelerate the development of AI-enabled treatments. Give your business an edge with our leading industry insights.

article thumbnail

Expanding Access: Digital Therapeutics and the Evolving Role of Pharmacists

Pharmacy Times

It's cognitive behavioral therapy packaged as a digital experience. I've even seen VR experiences, so it can be packaged in any type of digital experience. Getting this passed would mean broadening coverage within CMS, and then, hopefully, private insurers would follow suit.

article thumbnail

Harbour BioMed partners Otsuka on new T-cell therapy

Pharmaceutical Technology

June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook HBM7020 activates immune system T cells to target and destroy B cells and plasma cells involved in many autoimmune diseases. Credit: luchschenF /Shutterstock. Give your business an edge with our leading industry insights.